If dilution, it will be after the NDA filing. If the price goes up to above $4, it is a pretty good deal.
The cash is that low, apparently they have a plan for funding. Partnership announcement soon. Buy.
The target was $5 and reached one time after the first approval. The new target was raised to above $8 after the removal of phase III requirement by FDA, and has not reached yet.
It's understandable that share price drops after the earning announcement. It will come back once people realize there is a plan for financing.
Agree. I think the management has a plan for financing when the cash reaches that low level. Either a co-development with cash incoming, or a loan from the management themselves as they did before, or great news that they can do ATM, is possible. Otherwise, the cash should not reach that low before refiancing.
Hopefully, they sold some shares the past two days and now the balance is sufficient for the next quarters. The sold ATM shares at pretty good price in the past, around $3.5 per share.
My view is that they will have a distribution partner